Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 7/20 | 0.36 |
| ▸ | SI | P14410 | 6/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13183149 | 0.83 | ALOX5AP (0.37) | ALOX5APHSD11B1 | |
| SCHEMBL4449268 | 0.80 | GRIN2D (0.34) | ALOX5APHSD11B1 | |
| SCHEMBL3894280 | 0.80 | ALOX5AP (0.32) | ALOX5APHSD11B1 | |
| SCHEMBL15223673 | 0.80 | HSD11B1 (0.34) | ALOX5APHSD11B1 | |
| SCHEMBL6345473 | 0.77 | ALOX5AP (0.30) | ALOX5AP | |
| SCHEMBL13779595 | 0.77 | ALOX5AP (0.30) | ALOX5AP | |
| SCHEMBL10486297 | 0.75 | — | — | |
| SCHEMBL13779594 | 0.75 | — | — | |
| SCHEMBL31333039 | 0.75 | HSD11B1 (0.48) | HSD11B1 | |
| SCHEMBL152170 | 0.74 | ALOX5AP (0.37) | ALOX5APHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621990-B1 | THERMOSETTABLE COMPOSITIONS AND THERMOSETS THEREFROM | BLUE CUBE IP LLC (US) | 2016-02-24 | — | — | EP | claimed |
| EP-2621991-B1 | PROCESS FOR PREPARING EPOXY RESINS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-07-01 | — | — | EP | claimed |
| US-8962792-B2 | Process for preparing epoxy resins | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-02-24 | — | — | US | claimed |
| US-20140194554-A1 | EPOXY RESIN COMPOSITIONS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-07-10 | — | — | US | claimed |
| US-20130302336-A1 | DISULFIDE STABILIZED DVD-IG MOLECULES | UCB PHARMA S.A. (BE) | 2013-11-14 | — | — | US | claimed |
| US-20130237642-A1 | THERMOSETTABLE COMPOSITIONS AND THERMOSETS THEREFROM | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-09-12 | — | — | US | claimed |
| EP-2621990-A2 | THERMOSETTABLE COMPOSITIONS AND THERMOSETS THEREFROM | Dow Global Technologies LLC (US) | 2013-08-07 | — | — | EP | claimed |
| EP-2621994-A1 | EPOXY RESIN COMPOSITIONS | Dow Global Technologies LLC (US) | 2013-08-07 | — | — | EP | claimed |
| EP-2621991-A1 | PROCESS FOR PREPARING EPOXY RESINS | Dow Global Technologies LLC (US) | 2013-08-07 | — | — | EP | claimed |
| US-20130178601-A1 | PROCESS FOR PREPARING EPOXY RESINS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-07-11 | — | — | US | claimed |
| WO-2012044442-A1 | PROCESS FOR PREPARING EPOXY RESINS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-04-05 | — | — | WO | claimed |
| US-7250157-B2 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS (US) | 2007-07-31 | — | — | US | claimed |
| US-20060120976-A1 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS (US) | 2006-06-08 | — | — | US | claimed |
| US-6955804-B2 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DEMATICS (US) | 2005-10-18 | — | — | US | claimed |
| US-20040067209-A1 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS | 2004-04-08 | — | — | US | claimed |
| US-6623724-B2 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2003-09-23 | — | — | US | claimed |
| US-20020141952-A1 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2002-10-03 | — | — | US | claimed |
| WO-2002051395-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES | CODON PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | claimed |
| US-6267948-B1 | ADMINISTERING TO MAMMALIAN SKIN, HAIR, WOOL OR FUR DERMATOLOGICAL FORMULATION CONTAINING MELANOGENESIS STIMULATING AGENT WHICH STIMULATES MELANOGENESIS IN MELANOCYTES AND HYDROXY ACID TO ENHANCE MELANOGENESIS | APPLIED GENETICS INCORPORATED DERMATICS | 2001-07-31 | — | — | US | claimed |
| WO-1998055085-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS, INC. (US) | 1998-12-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020141952-A1 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | TYR, MITF, MC1R | ALOX5AP 1076/4885MGAM 4049/4885SI 4084/4885 |
| US-20130302336-A1 | DISULFIDE STABILIZED DVD-IG MOLECULES | EED, DRD2, PSMD14 | ALOX5AP 1950/4885MGAM 3582/4885SI 1988/4885 |
| US-20060120976-A1 | Dermatological compositions and methods | TYR, MITF, ALPG | ALOX5AP 617/4885MGAM 3863/4885SI 2611/4885 |
| US-20040067209-A1 | Dermatological compositions and methods | TYR, MITF, ALPG | ALOX5AP 617/4885MGAM 3863/4885SI 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.